discontinued in HIV-infected women who become pregnant (AIII). Furthermore, prophylaxis with systemic azoles should not be initiated during pregnancy. Moreover, prophylaxis against oropharyngeal or esophageal candidiasis using systemic antifungal medications should not be given to women with HIV infection who are pregnant. In the past, it was recommended that patients with oropharyngeal candidiasis who developed symptoms during pregnancy should be treated with an antifungal medication. However, due to concerns about the safety of antifungal medications during pregnancy, it is now recommended that patients with oropharyngeal candidiasis who develop symptoms during pregnancy should be managed with a combination of systemic and topical antifungal medications. This approach is expected to be effective in managing oropharyngeal candidiasis during pregnancy. The systemic antifungal medication should be started only after a thorough evaluation of the patient’s medical history and current medications.

Herpes Simplex Virus

Note: Severe mucocutaneous HSV infections (referring to primary care or specialist physician) require hospitalization.

Duration of therapy: 5-10 days

Alternative Therapy:
- Valacyclovir [500 mg bid (AIII)].
- Acyclovir 400 mg po bid (AIII).

Chronic Suppressive Therapy

For patients with severe recurrences (AIII)
- Pts who want to minimize the frequency of recurrences (AIII)
- For patients with severe recurrences (AIII)
- Acyclovir 500 mg po bid (AIII).

Herpes Zoster (Shingles)

Note: Treatment regimens vary with each patient according to the severity of the patient’s condition and immune status.

Note: Treatment regimens vary with each patient according to the severity of the patient’s condition and immune status.

Ulceration, Aphthous Continued

Tetracycline suspension: 125 mg/ml; swish for 1-2 minutes and expectorate bid 7 days or until lesions resolve.

Recurrent Aphthous Ulcerations

Fluocinonide 0.05% ointment is applied to affected areas after meals and at bedtime.
- Topical cidofovir is used to treat severe recurrences.
- Clobetasol propionate 0.05% ointment can be used to treat severe recurrences.
- Acyclovir 400 mg po bid (AIII).

LEUKOPLAKIA, ORAL HARY

Generally asymptomatic, no treatment required. Usually resolves with onset of Highly Active Antiretroviral Therapy.

PERIODONTITIS AND GINGIVITIS

- Betadine 10% solution (Povidone-iodine) is used during oral hygiene procedures.
- Chlorhexidine gluconate oral rinse 0.12% (Periord®) rinse with 15 mL bid for 30 seconds and spit out for 1-2 weeks.
- Flurbiprofen (Flapin®) 250 mg tid for 7-14 days (avoid if severe hepatic disease, alcoholic beverages or pregnancy/ lactation).
- Metronidazole 350 mg tid for 7-14 days.
- May consider prescribing antibiotics plus an antiinfluenzal agent.

ULCERATION, APHThous

Note: Treatment regimens vary with each patient according to the severity of the patient’s condition and immune status.

Note: Treatment regimens vary with each patient according to the severity of the patient’s condition and immune status.

HERPES SIMPLEX VIRUS

Note: Severe mucouscutaneous HSV infections (Referring to primary care or specialist physician)

Oral manifestations associated with HIV/AIDS

Pre-Exposure Prophylaxis (PrEP) & Post-Exposure Prophylaxis (PEP)

Treatment of Sexually Transmitted Diseases (STDs) in HIV-Infected Patients

Contact: Carol Stewart, MS, DDS, MS
Dental Director, Florida/Caribbean AIDS Education and Training Center, Inter-Associate Dean for Clinical Affairs/Professor, University of Florida College of Dentistry, Gainesville, Florida 352.627.9133 • cstewart@ufl.edu

Conditions are listed in alphabetical order:

CANDIDIASIS

Oral Manifestations Associated with HIV/AIDS

Provide state-of-the-art HIV health education, consultation, and resource materials to healthcare professionals throughout the region.

Chart Reviews
- Clinical Consultation

Herpes Simplex Virus

Note: Severe mucocutaneous HSV infections (Referring to primary care or specialist physician)

Oral manifestations associated with HIV/AIDS

Pre-Exposure Prophylaxis (PrEP) & Post-Exposure Prophylaxis (PEP)

Treatment of Sexually Transmitted Diseases (STDs) in HIV-Infected Patients

Tuberculosis (TB) in HIV/AIDS

Contact: Carol Stewart, MS, DDS, MS
Dental Director, Florida/Caribbean AIDS Education and Training Center, Inter-Associate Dean for Clinical Affairs/Professor, University of Florida College of Dentistry, Gainesville, Florida 352.627.9133 • cstewart@ufl.edu

Conditions are listed in alphabetical order:

CANDIDIASIS

Oral manifestations associated with HIV/AIDS

Pre-Exposure Prophylaxis (PrEP) & Post-Exposure Prophylaxis (PEP)

Treatment of Sexually Transmitted Diseases (STDs) in HIV-Infected Patients

Tuberculosis (TB) in HIV/AIDS

Note: Treatment regimens vary with each patient according to the severity of the patient’s condition and immune status.

Herpes Simplex Virus

Note: Severe mucocutaneous HSV infections (Referring to primary care or specialist physician)

Oral manifestations associated with HIV/AIDS

Pre-Exposure Prophylaxis (PrEP) & Post-Exposure Prophylaxis (PEP)

Treatment of Sexually Transmitted Diseases (STDs) in HIV-Infected Patients

Tuberculosis (TB) in HIV/AIDS

Contact: Carol Stewart, MS, DDS, MS
Dental Director, Florida/Caribbean AIDS Education and Training Center, Inter-Associate Dean for Clinical Affairs/Professor, University of Florida College of Dentistry, Gainesville, Florida 352.627.9133 • cstewart@ufl.edu

Conditions are listed in alphabetical order:

CANDIDIASIS

Oral manifestations associated with HIV/AIDS
Web-Based Education

The F/C AETC provides web-based education to increase the knowledge and skills of HIV healthcare providers. Programs are provided as both live and on-demand recorded webinars.

For more information, please visit:
www.FCAETC.org/education

HIV Prevention Program

This program provides resources to assist with HIV/AIDS prevention initiatives.

For more information, please visit:
www.USFCenter.org/prevention

© 2014
Developed by Carol Stewart, DDS, MS, University of Florida, College of Dentistry
Produced by the Florida/Caribbean AIDS Education and Training Center